Cytokine Signalling Forum

CME Courses

« Return to Overview

Management of Rheumatic Musculoskeletal Diseases in the COVID-19 Era

Management of Rheumatic Musculoskeletal Diseases in the COVID-19 Era
This symposium is independently developed by the Cytokine Signalling Forum and sponsored by AbbVie.

Release date: 06 August 2021
Estimated time to complete activity: 1 hour 30 minutes
Compatible with all modern internet browsers and mobile devices

After completing this activity, the learner will:
  • Gain insights from the global registries on COVID-19 in patients with RMD
  • Understand treatment guidelines for patients with RMD in the context of COVID-19
  • Understand the considerations for COVID vaccination in RMD and potential effects of different therapies on vaccine response
  • Consider how patient management changes employed during pandemic may affect their management going forward

This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.

Join us at the Cytokine Signalling Forum’s symposium at the EULAR 2021 annual conference. Here our expert faculty will review the most recent findings and advice on the management of patients during the COVID-19 pandemic. We will also discuss the changes in patient management, specifically focusing on the increased utilisation of telemedicine.

In this activity, Management of Rheumatic Musculoskeletal Diseases in the COVID-19 Era , international experts will discuss COVID-19 registries, key treatment guidelines, and vaccinations in the management of rheumatic musculoskeletal diseases.

Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

Module Presenter Video Questions
Management of Rheumatic Musculoskeletal Diseases in the COVID-19 Era
Professor Leonard Calabrese image
Professor Leonard Calabrese

Director & Professor of Medicine,
RJ Fasenmyer Center for Clinical Immunology, Cleveland Clinic Foundation, Ohio, USA

Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.

He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation.

He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles.

Prof. Leonard Calabrese (Bio)
Professor Kimme Hyrich image
Professor Kimme Hyrich

Professor of Epidemiology,
UK Centre for Epidemiology Versus Arthritis

Professor Hyrich completed her Bachelor of Science and Medical degree at the University of Manitoba in Canada. Following this, she trained in Internal Medicine in Winnipeg, Canada and completed a Fellowship in Rheumatology at the University of Toronto. She was awarded her PhD in 2005 subsequently working as a CIHR Research Fellow at the Arthritis Research UK Epidemiology Unit in Manchester. She is now Professor of Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary.

Her main research interests centre on outcomes in inflammatory arthritis, with a focus on pharmacoepidemiology. Professor Hyrich is a member of the EULAR registries group and the chief investigator for the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis as well as two national biologic registers for Juvenile Idiopathic Arthritis; the Versus Arthritis funded Safety of Biologics in Children with Rheumatic Diseases and the BSPAR Etanercept JIA Register. Professor Hyrich was instrumental in the collaboration of the global COVID-19 registers for patients with rheumatic disease.

Prof Kimme Hyrich (Bio)
Professor Robert Landewé image
Professor Robert Landewé

Professor of Rheumatology,
Amsterdam University Medical Center & Zuyderland Medical Center, Heerlen, The Netherlands

Robert Landewé is a professor of rheumatology at the Academic Medical Center / University of Amsterdam, The Netherlands, and is chair of the department of rheumatology at Zuyderland Medical Center Heerlen, The Netherlands.

Professor Landewé received his medical degree from Maastricht University in 1990 and defended his thesis on cyclosporine therapy in rheumatoid arthritis in 1994 in Leiden.

He received practical training in general internal medicine and rheumatology at Atrium Medical Center, Heerlen and in rheumatology at the University Hospital, Maastricht. He practices rheumatology in the Zuyderland Medical Center in Heerlen/Sittard, The Netherlands.

Currently, Professor Landewé is involved in outcome research and epidemiological research in the field of rheumatoid arthritis, spondyloarthritis and other rheumatic & musculoskeletal manifestations. He has extensive experience in the design and analysis of clinical trials and has a special interest in medical statistics. Professor Landewé has authored or co-authored more than 600 articles and many book chapters covering a variety of topics, but with an emphasis on clinical epidemiology, methodology, statistics, and guideline development (‘meta-research’). Recently he has developed an interest in -and published about- worldwide equity-issues pertaining to rheumatic diseases, as well as overdiagnosis and overtreatment.

He has led many EULAR recommendation initiatives on the management of systemic sclerosis, early arthritis, rheumatoid arthritis, axial spondyloarthritis, and recently on the management of SARS-CoV-2 in patients with inflammatory rheumatic diseases.

He is a regular reviewer for several general medicine-, rheumatology- and epidemiology journals.

Professor Landewé is a previous executive committee member of OMERACT, is board member and past president of the Assessment in Spondyloarthritis International Society (ASAS), previous executive board member of the Dutch Society of Rheumatology (responsible for quality of care issues), executive board member of the METEOR foundation (monitoring in rheumatology) and incoming chair of the Quality of Care committee of EULAR. He was the scientific chair of EULAR 2018 in Amsterdam.

Prof Robert Landewé (Bio)
Professor Christopher Edwards image
Professor Christopher Edwards

Honorary Chair of Clinical Rheumatology,
University of Southampton, Southampton, UK

Professor Christopher Edwards is Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology, University Hospital Southampton NHS Foundation Trust within Medicine at the University of Southampton. He graduated with honors from King's College London and trained at the Hammersmith and St George's Hospitals in London. He was a registrar for Professor Graham Hughes at the St Thomas' Hospital lupus unit and then undertook a period of research as a lecturer at the Kennedy Institute of Rheumatology at Imperial College under the supervision of Professor Ravinder Maini. He moved to Southampton in 2001 after working for a year as a rheumatology consultant at Tan Tock Seng Hospital in Singapore.

Professor Edwards is a clinical rheumatologist with research interests and expertise in the epidemiology and treatment of inflammatory rheumatic diseases including rheumatoid arthritis, lupus, psoriatic arthritis and ankylosing spondylitis.

He is a member of international committees working to produce guidelines for the best management of rheumatic diseases, leading a systematic review of guidelines for the use of radiology in the diagnosis and management of rheumatoid arthritis for EULAR. With expertise in the planning and delivery of trials in this area, including early stage trials, Professor Edwards has developed strong local and international partnerships with clinical and academic colleagues, centered on his role as clinical lead of the Southampton Musculoskeletal Research Unit. Professor Edwards also serves as Associate Editor for Rheumatology, and on the editorial board of Lupus.

Prof. Christopher Edwards (Bio)
89:32 0

Date of preparation: 06 August 2021